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Background: Extracellular Ca
2+ 
alters 
mGluR1α activity, but by an unknown 
mechanism. 
Results: Mutations in predicted Ca
2+
-
binding sites modulated the potency of both 
orthosteric and allosteric modulators. 
Conclusion: Ca
2+
 binding exerts multiple 
effects on mGluR1α. 
Significance: Understanding how Ca
2+
 
modulates mGluR1α activity could facilitate 
development of isoform-selective drugs 
and/or elucidate how to tune the actions of 
available drugs.  
SUMMARY: Metabotropic glutamate 
receptor 1α (mGluR1α), a member of the 
family C G protein-coupled receptors 
(GPCRs), is emerging as a potential drug 
target for various disorders including 
chronic neuronal degenerative diseases. 
In addition to being activated by 
glutamate, mGluR1α is also modulated by 
extracellular Ca
2+
. However, the 
underlying mechanism is unknown.      
Moreover, it has long been challenging to 
develop receptor-specific agonists due to 
homologies within the mGluR family, and 
the Ca
2+
-binding site(s) on mGluR1α may 
provide an opportunity for receptor-
selective targeting by therapeutics. In the 
present study, we show that our 
previously predicted Ca
2+
-binding site in 
the hinge region of mGluR1α is adjacent 
to the site where orthosteric agonists and 
antagonists bind on the extracellular 
domain of the receptor. Moreover, we 
have found that extracellular Ca
2+
 
enhances mGluR1α-mediated 
intracellular Ca
2+
 responses evoked by 
the orthosteric agonist, L-quisqualate. 
Conversely, extracellular Ca
2+
 diminishes 
the inhibitory effect of the mGluR1α 
orthosteric antagonist, (s)-MCPG. In 
addition, selective positive (Ro 67-4853) 
and negative (CPCCOEt) allosteric 
modulators of mGluR1α potentiate and 
inhibit responses to extracellular Ca
2+
, 
respectively, in a manner similar to their 
effects on the response of mGluR1α to 
glutamate. Mutations at residues 
predicted to be involved in Ca
2+
-binding, 
including E325I, have significant effects 
on the modulation of responses to the 
orthosteric agonist, L-quisqualate, and 
the allosteric modulator Ro 67-4853 by 
extracellular Ca
2+
. These studies reveal 
that binding of extracellular Ca
2+
 to the 
predicted Ca
2+
-binding site in the ECD of 
mGluR1α modulates not only glutamate-
evoked signaling but also the actions of 
both orthosteric ligands and allosteric 
modulators on mGluR1α. 
 The eight subtypes of metabotropic 
glutamate receptors (mGluRs) belong to 
family C of the G protein-coupled receptors 
(GPCRs) and possess a large extracellular 
domain (ECD), a transmembrane domain 
(TMD) and cytosolic C-terminal tail. The 
mGluRs are widely expressed in the central 
nervous system and play critical roles in 
regulating neuronal excitability and synaptic 
plasticity at both excitatory and inhibitory 
synapses (1). Extensive structural studies 
have revealed that the endogenous agonist, 
L-Glutamate (L-Glu), the major excitatory 
neurotransmitter in the central nervous 
system, binds at the hinge region of the ECD 
within the receptor’s Venus fly trap (VFT) 
motif to activate the protein. This 
subsequently stimulates phospholipase C 
(PLC) and leads to accumulation of inositol 
trisphosphate (IP3) and an increase of 
intracellular calcium concentration ([Ca
2+
]i) 
(2-4). 
 In recent years, mGluRs have received 
increasing interest as potential drug targets 
for the treatment of a range of psychiatric 
and neurological diseases (5) (Fig 1). The 
ligands targeting mGluRs can be classified 
as orthosteric agonists and antagonists as 
well as allosteric modulators. Orthosteric 
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agonists and antagonists induce and 
attenuate, respectively, the activity of the 
receptor by competitively binding to the L-
Glu binding pocket. L-Quisqualate (L-Quis), 
the most potent agonist of mGluR1 reported 
to date (6,7), has been speculated to share 
nearly the same binding pocket as L-Glu 
(8,9). In contrast, (s)-MCPG is an analog of 
L-Glu and is a non-selective competitive 
antagonist that has been shown to occupy 
the L-Glu binding pocket, thereby blocking 
the function of group I/II members in the 
mGluR family (10). On the other hand, 
allosteric modulators bind to sites other than 
the orthosteric center to affect the activity of 
the receptor. Ro 67-4853 is a positive 
allosteric modulator (PAM) of mGluR1 that 
enhances the potency of L-Glu by 
interacting with the TMD of the receptor. 
CPCCOEt is a negative allosteric modulator 
(NAM) that inhibits the activation of 
mGluR1 by L-Glu by specifically binding to 
a site that involves the third extracellular 
loop of mGluR1α (11).  
 Like other members of the family C 
GPCRs such as the calcium-sensing receptor 
(CaSR), mGluR1α senses [Ca2+]o using the 
extracellular domain (12,13). By transient 
expression of mGluR1α in oocytes, Kubo et 
al. demonstrated that mGluR1-mediated 
activation of Ca
2+
-activated Cl
-
 channels is 
modulated by [Ca
2+
]o in addition to L-Glu 
(4). Purkinje cells from mGluR1 knockout 
mice lose sensitivity to [Ca
2+
]o, with this 
sensitivity to [Ca
2+
]o being restored after 
mGluR1 was genetically reintroduced into 
the mice (14). There are sparse reports of 
[Ca
2+
]o affecting the action of various 
classes of compounds acting on mGluRs 
(15). However, it is not clear how [Ca
2+
]o is 
able to modulate the activity of mGluR1 or 
the actions of various mGluR1 ligands, and 
no Ca
2+
-binding sites have been identified in 
the 15 structures solved by X-ray 
crystallography to date (www.pdb.org). 
 Using our recently developed 
computational algorithm, we have identified 
a novel potential [Ca
2+
]o-binding site within 
the hinge region of the ECD of mGluR1α, 
adjacent to the reported L-Glu-binding site 
(16,17). It is comprised of D318, E325, 
D322, and the carboxylate side chain of the 
natural agonist, L-Glu. The carboxylate side 
chains of both L-Glu and D318 are involved 
in both L-Glu- and [Ca
2+
]o-binding. Our 
previous mutagenesis study indicated that 
binding of L-Glu and Ca
2+
 to their distinct 
but partially-overlapping binding sites 
synergistically modulates mGluR1α-
mediated activation of intracellular Ca
2+
 
([Ca
2+
]i signaling. Mutating the L-Glu-
binding site completely abolished L-Glu 
signaling, while leaving its Ca
2+
-sensing 
capability largely intact. Mutating predicted 
Ca
2+
-binding residues not only abolished or 
significantly reduced the sensitivity of 
mGluR1α to [Ca2+]o but also, in some cases, 
to L-Glu (18). 
 In the present study, we first 
demonstrated that our predicted Ca
2+
-
binding site is adjacent to the orthosteric 
agonist and antagonist interaction sites. We 
then examined the role of [Ca
2+
]o in 
modulating the actions of different 
orthosteric ligands acting on mGluR1, 
including L-Quis, (s)-MCPG, as well as 
reciprocal interactions between Ca
2+
 and the 
mGluR1 allosteric modulators, Ro 67-4853 
and CPCCOEt. Our results suggest [Ca
2+
]o 
modulates the sensitivity of mGluR1α to not 
only orthosteric agonists and antagonists but 
also to allosteric modulators, likely by 
interacting with the predicted [Ca
2+
]o-
binding site in the ECD of the receptor. 
EXPERIMENTAL PROCEDURES 
 Dock L-Quis to ECD-mGluR1α using 
Autodock-vina and hinge motion analysis. 
To elucidate L-Quis’s binding to the ECD of 
mGluR1α, L-Quis was docked into the 
crystal structure (1EWK). After removing 
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the coordinates of the bound endogenous 
ligand, L-Glu, the pdb file was loaded into 
Autodock tools to add polar hydrogen atoms 
and choose the docking center and grid box. 
The docking work was carried out by 
Autodock tool – Vina (Scripps). The binding 
residues were analyzed by measuring the 
atoms within 6 Å of L-Quis. The L-Glu and 
the (s)-MCPG binding sites within the hinge 
region were analyzed using Dymdon.  
 MD simulation and correlation analysis 
using Amber. The initial coordinates for all 
the simulations were taken from a 2.20 Å 
resolution x-ray crystal structure with 
PDBID 1EWK (19). The AMBER 10 suite 
of programs (20) was used to carry out all of 
the simulations in an explicit TIP3P water 
model (21), using the modified version of 
the all-atom Cornell et. al. (22) force field 
and the re-optimized dihedral parameters for 
the peptide ω-bond. (23) The crystal 
structure contains only PHE substrate. Ca
2+
 
ion was placed at the suggested Ca
2+
-
binding site that is defined by residues D318, 
D322, and E325. An initially 2 ns simulation 
was performed using NOE restraint during 
the equilibration in order to reorient the side 
chains residues in the Ca
2+
-binding site, but 
no restraints were used during the actual 
simulation. A total of four MD simulations 
were carried out for 50 ns each on wild type 
and three mutant mGluRs. The mutations 
were D318I, D322I, and E325I. First, our 
structures were minimized to achieve the 
lowest-energy conformation in each 
complex. The structures were then 
equilibrated for 2 ns, starting the MD 
simulations from the equilibrated structures. 
During the simulations, an integration time 
step of 0.002 ps was used to solve Newton’s 
equation of motion. The long-range 
electrostatic interactions were calculated 
using Particle Mesh Ewald method (24) and 
a cutoff of 9.0 Å was applied for non-
bonded interactions. All bonds involving 
hydrogen atoms were restrained using the 
SHAKE algorithm (25). The simulations 
were carried out at a temperature of 300 K 
and a pressure of 1 bar. A Langevin 
thermostat was used to regulate the 
temperature with a collision frequency of 
1.0 ps
-1
. The trajectories were saved every 
500 steps (1ps). The trajectories were then 
analyzed using the ptraj module in Amber 
10.  
 Constructs, site-directed mutagenesis, 
and expression of mGluR1α variants. The 
red fluorescent protein, mCherry, was 
genetically tagged to the C-terminal of 
mGluR1α by a flexible linker—
GGNSGG(18). Point mutations were 
introduced using a site-directed mutagenesis 
kit (Strategene). HEK293 cells were seeded 
and cultured on glass coverslips. MGluR1α 
and its mutants were transfected into cells 
utilizing lipofectamine 2000 (Invitrogen). 
The cells were then incubated for two 
additional days, so that mGluR1α and its 
mutants were expressed at sufficient levels 
for study. Cells were fixed on the coverslips 
with 4% formaldehyde, and nuclei were 
stained with DAPI. The expression of 
mGluR1α and its variants were detected by 
measuring red fluorescence using confocal 
microscopy at 587 nm.  
 Determining the effect of [Ca
2+
]o on 
activation of mGluR1α and its mutants by L-
Quis. Measurement of [Ca
2+
]i was 
performed as described (13). In brief, wild 
type mGluR1α was transiently transfected 
into the cells and cultured for two additional 
days. The cells on the coverslips were 
subsequently loaded using 4 μM Fura-2 AM 
in 2 mL physiological saline buffer (10 mM 
HEPES, 140 mM NaCl, 5 mM KCl, 0.55 
mM MgCl2, 1 mM CaCl2 and pH 7.4) for 30 
min. The coverslips were then mounted in a 
bathing chamber on the stage of a 
fluorescence microscope at room 
temperature. Fura-2 emission signals at 510 
nm from single cells excited at 340 or 380 
nm were collected utilizing a Leica DM6000 
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fluorescence microscope in real time as the 
concentration of L-Quis was progressively 
increased in the presence or absence of 
[Ca
2+
]o. The ratio of fluorescence emitted at 
510 nm resulting from excitation at 340 or 
380 nm was further analyzed to obtain the 
[Ca
2+
]i response as a function of changes in 
L-Quis. Only the individual cells with 
mCherry expressed were selected for 
analysis. 
 Measurement of [Ca
2+
]i responses of 
mGluR1α to [Ca2+]o or L-Glu in the 
presence of 0.5 mM s-MCPG. The methods 
for measuring [Ca
2+
]i responses were as 
described above. In the presence of (s)-
MCPG, the cells were incubated with 0.5 
mM (s)-MCPG in a L-Glu-free saline buffer 
for 30 more minutes after Fura-2 loading. 
Then, the sensitivity of mGluR1α to [Ca2+]o 
or added L-Glu was measured either by 
increasing the concentration of L-Glu in the 
presence of 1.8 mM [Ca
2+
]o, or by 
increasing [Ca
2+
]o in a stepwise manner in 
the saline buffer with or without 0.5 mM (s)-
MCPG. The L-Glu concentrations were 
recorded at which the [Ca
2+
]i responses of 
mGluR1α were first observed and then were 
saturated. 
 Determining the effects of [Ca
2+
]o on the 
potency of Ro 67-4853 on mGluR1α. Fura-
2AM was used for monitoring [Ca
2+
]i in real 
time as described above. Ro 67-4853 did not 
potentiate mGluR1α in the absence of L-Glu 
(26,27). To obtain the [Ca
2+
]i readout, 
HEK293 cells expressing mGluR1α were 
pre-incubated with 0.5 mM Ca
2+
 and 5 nM 
Ro 67-4853 for at least 10 minutes. Cells 
loaded with Fura-2AM were mounted onto a 
chamber perfused with saline buffer. By 
increasing the concentration of Ro 67-4853 
stepwise in the presence of 0.5 mM or 1.8 
mM [Ca
2+
]o [Ca
2+
]i was recorded as before 
by the ratiometric change of fura-2AM in 
response to changes in [Ca
2+
]i. The effect of 
[Ca
2+
]o was analyzed by comparing the 
intracellular Ca
2+
 responses elicited by Ro 
67-4853 at two different concentrations of 
Ca
2+
 in the perfusion buffer. To determine 
the effect of Ro 67-4853 on the sensitivity of 
mGluR1α to [Ca2+]o, an additional 30 nM or 
300 nM Ro 67-4853 was applied as [Ca
2+
]o 
was increased. 
 Measurement of [Ca
2+
]i responses of 
mGluR1α to [Ca2+]o or L-Glu in the 
presence of CPCCOEt. After the coverslip 
was mounted in the microscope, the cells 
were perfused with a saline buffer 
containing 0, 5 or 40 µM CPCCOEt for 
more than 10 min. Increasing concentrations 
of [Ca
2+
]o or L-Glu were added to the 
chamber in the presence of varying 
concentrations of CPCCOEt, and the [Ca
2+
]i 
response was recorded. 
 Determining the effects of [Ca
2+
]o on 
[
3
H]-L-Quis binding to mGluR1α and its 
mutants. HEK293 cells transiently 
transfected with wild type mGluR1α or its 
mutants were maintained in a 5% CO2 37
o
C 
incubator for an additional 48 hours as 
before. Cells were then collected in ice cold 
hypotonic buffer (20 mM HEPES, 100 mM 
NaCl, 5 mM MgCl2, 5 mM KCl, 0.5 mM 
EDTA, and 1% protease inhibitors at pH 
7.0-7.5). The cell pellet was washed twice 
more using hypotonic buffer to remove the 
L-Glu in the cellular debris. The crude 
membrane protein (100 µg) was mixed with 
30 nM [
3
H]-L-Quis in 100 µL of hypotonic 
buffer. The nonspecific binding was 
determined by measuring bound [
3
H]-L-
Quis in the presence of 200 µM L-Glu. To 
study the effects of [Ca
2+
]o on L-Quis 
binding to mGluR1α, increasing 
concentrations of [Ca
2+
]o were applied. The 
reaction mixtures were incubated on ice for 
at least 1 hour, and the membrane-bound 
[
3
H]-L-Quis was captured on filter paper 
using a Brandel cell harvester under vacuum. 
The filter paper was then transferred to 
scintillation fluid, and [
3
H]-L-Quis was 
detected using a Beckman LS 6500 multi-
purpose scintillation counter.  
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RESULTS 
 
 Predicted [Ca
2+
]o-binding site is 
adjacent to orthosteric agonist and 
antagonist binding sites. Using our recently 
developed computational algorithms, we 
have identified a novel potential Ca
2+
-
binding site at the hinge region of the ECD 
of mGluR1α (18). Fig. 1 shows that the 
predicted Ca
2+
-binding site is comprised of 
D318, E325, D322, and the carboxylate side 
chain of the natural agonist, L-Glu, in the 
hinge region in the ECD of mGluR1α, 
adjacent to the reported L-Glu-binding site. 
D318 is involved in both L-Glu- and Ca
2+
-
binding (18).  
 Using the crystal structure (1EWK, 
closed-open form) of the receptor’s ECD 
and Autodock-Vina program, we modeled 
the binding site for the orthosteric agonist, 
L-Quis. As shown in Fig. 1B, the docked 
binding site of the agonist, L-Quis, 
corresponds well with the L-Glu-binding 
residues previously suggested by the crystal 
structure. Our predicted Ca
2+
-binding site is 
also adjacent to the L-Quis pocket and 
interacts with L-Quis similarly to L-Glu (Fig. 
1B). In the reported crystal structure of 
mGluR1 complexed with an orthosteric 
antagonist, (s)-MCPG (PDBID: 1ISS), (s)-
MCPG interacts with Y74, W110, S165, 
T188, and K409 in lobe one (LB1) and 
D208, Y236 and D318 in lobe two (LB2) 
(Fig 1B) (10). It shares with L-Glu most of 
the residues of the L-Glu-binding pocket 
(10) and is also adjacent to our predicted 
Ca
2+
-binding site.  
 We next performed Molecular Dynamics 
simulations to reveal any possible 
interaction between our predicted [Ca
2+
]o-
binding site and the orthosteric ligand-
binding site. Residues involved in the 
[Ca
2+
]o-binding pocket, such as D318, D322, 
and E325, have strong correlated motions, as 
expected given their roles as [Ca
2+
]o-binding 
ligands. In addition, residues D318 and 
R323 residing within the same loop as the 
predicted Ca
2+
-binding site are also 
concurrently correlated. As shown in Figure 
2, most of the critical L-Glu-binding 
residues, including W110, S165, T188, 
D208, Y236, D318 and R323, are well 
correlated to the [Ca
2+
]o-binding site (D318, 
D322 and E325). However, mutations at the 
charged residues involved in [Ca
2+
]o-binding, 
such as D318I and E325I, markedly 
attenuate the correlation of the Ca
2+
-binding 
site with the L-Glu binding pocket. The 
Ca
2+
-binding site in mutant D318I only 
correlates with G293 and D208, and mutant 
D325I only correlates with Y236 and G293. 
The mutant D322I also exhibits impaired 
correlation between the [Ca
2+
]o-binding site 
and L-Glu-binding site, but to a lesser 
degree. As shown in Table 1, D318 in the 
[Ca
2+
]o-binding site still correlates with four 
residues in the L-Glu-binding pocket (Fig. 
2). Similarly, residues that are involved in 
binding L-Quis and (s)-MCPG also correlate 
well with residues involved in the predicted 
[Ca
2+
]o-binding site. Results from these 
analyses and our previous studies on the 
effect of binding of [Ca
2+
]o to its site on L-
Glu-mediated activation of mGluR1 lead us 
to hypothesize that [Ca
2+
]o regulates the 
effects of orthosteric ligands on mGluR1α.  
 Ca
2+
 enhances sensitivity of activation of 
mGluR1α by L-Quis by increasing [3H]-L-
Quis binding via interaction with the 
[Ca
2+
]o-binding site of the receptor. To test 
the effect of [Ca
2+
]o on the activation of 
mGluR1α by the orthosteric agonist, L-Quis, 
we performed a single cell  fluorescence 
imaging assay by measuring changes in 
[Ca
2+
]i using HEK293 cells transiently 
transfected with mGluR1α and loaded with 
fura-2. To eliminate any potential effect of 
trace L-Glu secreted from cells, experiments 
were conducted using continuous 
superfusion of cells with an L-Glu-free 
buffer. Fig. 3A-D show that L-Quis induces 
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intracellular calcium responses mediated by 
mGluR1 in a similar manner to the 
activation of the receptor by L-Glu. [Ca
2+
]o 
behaves as a PAM of the L-Quis response 
and induces a leftward shift in the L-Quis 
CRC (concentration-response curve) for 
activation of mGluR1a (Fig. 3A-D).  In the 
absence of [Ca
2+
]o (Ca
2+
-free buffer with 
less than 2 µM calcium), the EC50 for the 
activation of mGluR1a by L-Quis is 12.8 
nM. The addition of 1.8 mM [Ca
2+
]o reduces 
the EC50 of L-Quis to 2.8 nM (about 4.6 
fold)  (Fig. 3D, Table 2). This [Ca
2+
]o-
mediated increase in the potency of L-Quis 
is similar to the effect of [Ca
2+
]o on the 
activation of mGluR1 by its natural agonist, 
L-Glu (18).  
 To test whether this [Ca
2+
]o-mediated 
increase in the potency of L-Quis occurs via 
our predicted [Ca
2+
]o-binding site in the 
ECD of the receptor, we then examined 
three mGluR1 variants with mutations 
around the [Ca
2+
]o-binding site adjacent to 
the orthosteric binding site at the hinge 
region. The negatively charged side chain of 
E325 has previously been shown to be 
important for [Ca
2+
]o-binding by mGluR1 
and not directly involved in L-Glu-binding 
(18). Removal of the [Ca
2+
]o-binding ligand 
residue E325 in the mGuR1 variant E325I 
reduces potency, increasing the EC50 from 
12.6 to 20 nM in the absence of [Ca
2+
]o (Fig 
3D and Table 2). Importantly, this mutation 
significantly reduces the [Ca
2+
]o-mediated 
enhancement in potency for L-Quis from 
4.6-fold to 1.6-fold in 1.8 mM [Ca
2+
]o, 
although both the potency and efficacy of L-
Quis-mediated activation of the E325I 
mutant are still enhanced relative to WT 
mGluR1 (Fig 3A-D). As L-Glu could 
potentially serve as a ligand for binding of 
Ca
2+
 to its pocket, L-Glu- or L-Quis-binding 
could rescue the mutated Ca
2+
-binding 
pocket, thus enhancing the Ca
2+
 sensitivity 
of the mutant. On the other hand, mutant 
D322I exhibits WT-like behavior in its 
response to L-Quis both in the absence and 
presence of [Ca
2+
]o (Fig. 3A-D, Table 2), 
consistent with D322 contributing to 
[Ca
2+
]o-binding to a lesser degree, with only 
its main chain oxygen serving as a ligand 
atom. We also observed WT-like 
modulation of the L-Glu response of D332I 
by Ca
2+
 (18). These [Ca
2+
]i imaging data 
suggest that [Ca
2+
]o plays a key role in 
modulating the activation of mGluR1α by L-
Quis, possibly via interaction of [Ca
2+
]o at 
the predicted [Ca
2+
]o-binding site. 
 We utilized a direct binding assay with 
radioactive L-Quis ([
3
H]-L-Quis) to assess 
the impact of [Ca
2+
]o on the binding of [
3
H]-
L-Quis to mGluR1α or its variants with 
mutations at the predicted [Ca
2+
]o-binding 
ligand residues in the absence or presence of 
[Ca
2+
]o. L-Quis binds to the wild type 
receptor expressed in HEK293 with a KD in 
the range of 30 nM. L-Glu reduces L-Quis 
binding by competing for the similar 
orthosteric binding pocket (Figs. 1B, 4B 
Insert). [Ca
2+
]o significantly enhances L-
Quis-binding to the wild type receptor with 
an EC50  in the range of 0.3 mM (Fig 3E, 
Table 2). Variant E325I, with removal of 
negative charge on the key [Ca
2+
]o-binding 
residue E325, abolishes L-Quis binding, and 
this effect is not influenced by the addition 
of L-Glu or [Ca
2+
]o (Kd > 20 mM) (Table 2). 
On the other hand, variant D322I retains the 
binding properties of the wild type receptor 
for L-Quis suggesting its less essential role 
in L-Quis binding (Fig 3E), which is 
consistent with its role in activation of the 
[Ca
2+
]i responses described earlier. Taken 
together, both the studies of [Ca
2+
]i 
responses and L-Quis-binding suggest that 
[Ca
2+
]o enhances the activation of mGluR1 
by L-Quis by directly modulating binding of 
L-Quis to mGluR1 through an interaction 
with predicted [Ca
2+
]o-binding site 1 in the 
hinge region. 
 (s)-MCPG reduces the sensitivity of 
mGluR1α to L-Glu and [Ca2+]o. The effects 
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of [Ca
2+
]o on various mGluR1 ligands acting 
by different mechanisms on mGluR1 were 
evaluated using L-Glu as the orthosteric 
agonist, since it is the physiological 
activator of the receptor in vivo. As shown 
in Figure 4, (s)-MCPG induces a 
concentration-dependent decrease in the L-
Glu-evoked [Ca
2+
]i response (Fig. 4A).  A 
concentration of 0.5 mM (s)-MCPG elicits a 
parallel rightward shift in the L-Glu CRC, 
and increases the EC50 for L-Glu from 1.7 to 
3.7 µM. This is consistent with the known 
action of MCPG as a competitive antagonist 
at the orthosteric L-Glu binding site.  
 Interestingly, Fig 4A shows that MCPG 
also induces a concentration-dependent 
inhibition of the 5 mM [Ca
2+
]o-induced 
[Ca
2+
]i response, even in the absence of 
added L-Glu. Unlike the effect of MCPG on 
the response to L-Glu, MCPG does not 
completely block the response to [Ca
2+
]o. 
This is consistent with the hypothesis that 
MCPG inhibits the response to [Ca
2+
]o by 
acting at a site distinct from the one that 
allosterically regulates the response to 
[Ca
2+
]o. MCPG also induces a rightward 
shift in the [Ca
2+
]o CRC. The EC50 for 
[Ca
2+
]o increases by ~1.7 fold (from 3.5 to 
6.0 mM at 0 and 0.5 mM MCPG, 
respectively) (Fig. 4C, Table 3). The 
maximal response to [Ca
2+
]o was not 
affected by 0.5 mM MCPG. However, as 
noted above, higher concentrations of 
MCPG could not fully block the maximal 
effect of 5 mM [Ca
2+
]o. 
 NAM CPCCOEt noncompetitively 
inhibits both L-Glu-induced and [Ca
2+
]o-
induced activation of mGluR1α. CPCCOEt 
is known as a selective, non-competitive 
negative allosteric modulator (NAM) of 
mGluR1 that binds to residues T815 and 
A818 in the 7th TMD of the receptor (28) 
(Fig. 1). As shown in Fig. 5A, the L-Glu-
triggered [Ca
2+
]i response is significantly 
depressed in the presence of 5 and 40 µM 
CPCCOEt. In the presence of 40 µM 
CPCCOEt, the maximal response decreases 
to only about half of the control level, while 
the EC50 value increases from 1.7 to 10.1 
µM (Fig. 5A, Table 4). To determine the 
effects of CPCCOEt on the activation of 
mGluR1α by [Ca2+]o, we next examined the 
effect of CPCCOEt on [Ca
2+
]o-induced 
[Ca
2+
]i responses. Fig. 5B reveals that 
CPCCOEt significantly inhibits the [Ca
2+
]o 
sensitivity of mGluR1α. In the presence of 5 
µM CPCCOEt, the EC50 of mGluR1α for 
[Ca
2+
]o was increased from 3.5 to 14.7 mM. 
A concentration of 40 µM CPCCOEt 
produces an even higher EC50 value of 28.7 
mM (Fig. 5B, Table 4). The maximal 
response is also significantly decreased by 
40 µM CPCCOEt, although the maximal 
response with 5 µM CPCCOEt is still 
comparable. This indicates that 30 mM 
[Ca
2+
]o cannot completely reverse the 
antagonism induced by CPCCOEt, and thus 
the inhibitory effects of CPCCOEt on the 
response of mGluR1α to [Ca2+]o appears to 
be non-competitive (Fig. 5B, Table 4).
 The mGluR1α PAM Ro 67-4853 
potentiates activation of mGluR1 by [Ca
2+
]o. 
The finding that CPCCOEt inhibits 
activation of mGluR1 by [Ca
2+
]o suggests 
that the CPCCOEt site, in the 
transmembrane-spanning domain of 
mGluR1, and the [Ca
2+
]o-binding site, in the 
ECD of the receptor, interact in a manner 
similar to the interactions between the 
orthosteric L-Glu binding site and the 
allosteric CPCCOEt site. We performed 
analogous experiments to determine whether 
the mGluR1 PAM, Ro 67-4853, which binds 
to the extracellular loops of the TMDs of 
mGluR1α, (2,29) (Fig. 1B), can also 
potentiate responses to [Ca
2+
]o. Fig 6A 
shows that L-Glu-induced activation of WT 
mGluR1α is enhanced by the addition of 10 
or 100 nM Ro 67-4853 using single cell 
[Ca
2+
]i imaging. We then examined the 
effects of Ro 67-4853 on the [Ca
2+
]o 
sensitivity of wild type mGluR1α in the 
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absence of L-Glu. Fig. 6B shows that both 
30 and 300 nM Ro 67-4853 enhanced the 
[Ca
2+
]i response induced by [Ca
2+
]o, 
reducing the EC50 values for [Ca
2+
]o from 
3.5 mM to 2.1 and 0.7 mM, respectively. As 
with the effect of Ro 67-4853 on the 
response to L-Glu, the maximal response to 
[Ca
2+
]o is not changed by Ro 67-4853 (Fig. 
6B and Table 5). 
 To further evaluate the effect of Ro 67-
4853 on mGluR1α, HEK293 cells 
transiently expressing mGluR1α were pre-
incubated with 0.5 mM Ca
2+
 and 5 nM Ro 
67-4853 for up to 10 minutes, and then the 
responses to multiple concentrations of Ro 
67-4853 were tested. In the presence of 0.5 
mM [Ca
2+
]o, Ro 67-4853 enhances L-Glu-
induced mGluR1α activity in a 
concentration-dependent manner. Increasing 
[Ca
2+
]o to 1.8 mM significantly increases the 
potency of low dosage of Ro 67-4853 for 
mGluR1α (P < 0.05) (Fig. 6C). At the same 
time, the EC50 value decreases from 20.7 to 
10.0 nM (Fig. 6C, Table 5). Interestingly, 
[Ca
2+
]i  oscillations are observed when the 
cells are treated with Ro 67-4853 (data not 
shown). Similar to the Ca
2+
-sensing receptor, 
three different patterns of response are noted 
(30). Most of the cells display a transient 
spike in [Ca
2+
]i. Some cells start oscillating 
after the first peak, while others have a 
transient peak and oscillations first appear a 
few minutes later. By analyzing the number 
of cells oscillating out of the total number of 
responsive cells, 1.8 mM [Ca
2+
]o 
significantly increases the number of 
oscillatory cells compared to the cells in 0.5 
mM [Ca
2+
]o. The starting point of oscillation 
is also shifted leftward (Data not shown). 
This suggests that [Ca
2+
]o enhances the 
potency of Ro 67-4853 in activating 
mGluR1α. 
 To understand whether this modulation 
by [Ca
2+
] o of the action of this allosteric 
modulator  acting via the TMDs is indeed a 
result of [Ca
2+
]o-binding to the predicted 
[Ca
2+
]o-binding site in the ECD (e.g., Fig. 1), 
we then performed studies using an mGluR 
variant with a key [Ca
2+
]o-binding ligand 
residue mutated, E325I. Fig. 1B shows that 
E325 is not directly involved in L-Glu-
binding, and variant E325I is able to sense 
L-Glu in a manner similar to WT  (18). Fig. 
7A shows that addition of 30 µM L-Glu 
enhances the responsiveness of E325I to Ro 
67-4853. Of note, Fig 7B shows that E325I 
responds to 10 µM Ro 67-4853 in the 
absence of L-Glu in [Ca
2+
]o-free saline. 
Increasing [Ca
2+
]o from 0.5 to 1.8 mM does 
not affect the sensitivity of E325I to Ro 67-
4853, but elevating [Ca
2+
]o increases the 
responses of WT mGluR1α to 300 nM Ro 
67-4853 (Fig. 7B). This suggests that 
mutating the Ca
2+
-binding site (E325I) 
eliminates the effect of Ca
2+
 on Ro 67-4853, 
but not on WT mGluR1α. To determine if 
the receptors were saturated by Ro 67-4853, 
higher concentrations of the PAM were 
applied to both WT mGluR1 and E325I. As 
shown in Fig. 7B, higher concentrations of 
Ro 67-4853 increase the responses of both 
WT mGluR1 and E325I. This result 
suggests that [Ca
2+
]o-binding at its predicted 
site in the hinge region is essential for the 
positive allosteric action of this modulator.  
 
DISCUSSION 
 In this paper, we have demonstrated that 
[Ca
2+
]o has significant modulating effects on 
the actions of various orthosteric and 
allosteric ligands on mGuR1a, as assessed 
using a functional readout (i.e., [Ca
2+
]i 
responses) in receptor-transfected HEK293 
cells. [Ca
2+
]o exerted several different 
effects on the compounds studied here, 
including the orthosteric agonist, L-Quis, the 
orthosteric antagonist, MCPG, and allosteric 
modulators, e.g., the PAM Ro 67-4853 and 
the NAM CPCCOEt. 
As shown in Fig. 1, the predicted 
[Ca
2+
]o-binding site partially overlaps the 
predicted orthosteric binding site for the 
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agonist, L-Quis, and the antagonist, MCPG. 
We have previously reported the effects of 
[Ca
2+
]o on [L-Glu]o-induced activation of 
the receptor. Consistent with this, we have 
shown here that activation of mGluR1α by 
L-Quis was enhanced by [Ca
2+
]o in a similar 
manner. Through binding to the Ca
2+
-
binding site on the ECD of mGluR1, [Ca
2+
]o 
was capable of inducing the hydrolysis of 
PIP2, thus increasing IP3 and Ca
2+
 release 
from the ER (18). As reported, [Ca
2+
]o was 
shown to synergistically activate mGluR1α 
with L-Glu (18). However, activation of 
GPCRs is also known to induce Ca
2+
 influx 
through store-operated Ca
2+
 entry channels 
(31,32). By utilizing Gd
3+
, an inhibitor of 
these Ca
2+
 channels, we noted that mGluR1a 
still could induce an increase in [Ca
2+
]i (18). 
But comparing this increase to the [Ca
2+
]o-
induced concentration response curve, the 
Gd
3+
 response after the transient increase in 
[Ca
2+
]i returned the curve back to the 
baseline (33). This suggests that Ca
2+
 release 
from the ER predominantly induces a 
transient peak, while Ca
2+
 influx elevates the 
plateau portion of the response. We also 
further demonstrated that increasing [Ca
2+
]o 
enhanced L-Quis binding to HEK293 cells 
over-expressing mGluR1α, while the mutant 
E325I abolished this effect of [Ca
2+
]o on the 
activation of mGluR1 (Fig 3). Moreover, a 
clear difference in L-Quis and L-Glu 
binding was observed in the presence of 
physiological levels of [Ca
2+
]o. [Ca
2+
]o in the 
synaptic cleft changes at the range from 0.8 
to 1.5 mM (34), and mGluR1α is known to 
respond the [Ca
2+
]o change between 0.5 and 
1.5 mM (18). Using purified ECD of 
mGluR1α, Jingami et al. reported that 
[Ca
2+
]o enhances the increase in Trp 
fluorescence induced by L-Quis and L-Glu 
(15), although [Ca
2+
]o was reported to have 
no effect on L-Quis binding (35). Nash et al. 
also observed that [Ca
2+
]o produces a higher 
plateau [Ca
2+
]i response and greater IP3 
accumulation in CHO cells mediated by 
mGluR1α (36), although the transient 
increase in [Ca
2+
]i was not affected. Thus, 
our observation that [Ca
2+
]o enhanced both 
L-Quis-induced [Ca
2+
]i responses and L-
Quis binding to the receptor has a 
physiological implication similar to the 
modulation by [Ca
2+
]o of the action of L-Glu 
on mGluR1α. Fig 1 shows that the predicted 
[Ca
2+
]o-binding site is located adjacent to the 
(s)-MCPG binding pocket in mGluR1 in the 
X-ray structure (PDBID: 1ISS), which is in 
the hinge region of the ECD and occupies 
most of the residues involved in L-Glu-
binding (10). We tested the effects of 
gradually increasing concentrations of the 
orthosteric antagonist, (s)-MCPG, on 
[Ca
2+
]o-induced signaling by mGluR1α. As 
shown in Fig 4, (s)-MCPG reduced the 
[Ca
2+
]o sensitivity of mGluR1α (Fig. 4A and 
C). Here we have shown that increases in 
the concentrations of either [Ca
2+
]o or L-Glu 
overcame the inhibition induced by (s)-
MCPG (Fig. 4). It is interesting to note that 
(s)-MCPG could not completely block the 
[Ca
2+
]o sensitivity of mGluR1 (Fig. 4C). 
[Ca
2+
]o-induced responses mediated by 
mGluR1α were found to be only partially 
antagonized by (s)-MCPG (4). (s)-MCPG, 
was shown to have the capacity to 
completely inhibit L-Glu-potentiated Ca
2+
-
activated Cl
-
 currents in Xenopus laevis 
oocytes transiently expressing mGluR1 (4). 
These data support our hypothesis that 
[Ca
2+
]o modulates the effects of orthosteric 
ligands on mGluR.  
  The observed [Ca
2+
]o-modulated 
orthosteric effect is likely dependent on 
communication of the predicted [Ca
2+
]o-
binding site with the adjacent binding site 
for orthosteric agonists and antagonists. We 
first showed that the L-Quis binding pocket 
predicted here using AutoDock-Vina 
overlaps extensively with the L-Glu-binding 
pocket in the reported crystal structure 
(Table 6). The side-chain of D318 is 
involved in both [Ca
2+
]o- and agonist-
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binding. In our earlier study, the mutation 
D318I was shown to abrogate both the 
sensitivity to [Ca
2+
]o and responsiveness to 
L-Glu (18). In this study, it also completely 
eliminated L-Quis-mediated activation of 
mGluR1 (Fig. 3E). This finding is supported 
by a previous report that the mutants T188A, 
D208A, Y236A and D318A abolished the 
sensitivity of the receptor to both L-Quis 
and L-Glu, while the mutants R78E and 
R78L exhibited clearly impaired L-Quis 
binding (8,9). The key residue E325 is 
involved in [Ca
2+
]o-binding, and the mutant, 
E325I, indeed significantly impaired both 
the [Ca
2+
]o and L-Glu sensitivity of the 
receptor (Fig. 3). On the other hand, variant 
D322I produced less reduction of the 
modulatory effects of [Ca
2+
]o  on both L-
Quis and L-Glu agonist action and is 
consistent with its lesser role in [Ca
2+
]o-
binding with a contribution of only a main 
chain ligand atom (Fig 1).  
Our observed effect of [Ca
2+
]o on 
responses to orthosteric agonists and 
antagonists of mGluR1 is consistent with 
Molecular Dynamics Simulation studies 
performed here on the correlated motions of 
the hinge region in the ECD of mGluR (Fig 
2, Table 1). We have observed a strong 
correlation among residues in the predicted 
[Ca
2+
]o-binding site and residues involved in 
the orthosteric binding sites shared by L-Glu, 
L-Quis and MGPG. Interestingly, mutation 
of the [Ca
2+
]o-binding site largely removed 
this correlation. Fig. 1A shows that the 
predicted [Ca
2+
]o-binding site at the hinge 
region is conserved in the group I mGluRs, 
e.g., mGluR1 and mGluR5 (18), calcium-
sensing receptor and T1R3, a taste receptor 
for [Ca
2+
]o, (37). In our previous study, 
[Ca
2+
]o exhibits synergy with L-Glu in 
activating mGluR1α (18). We have further 
demonstrated here the effect of [Ca
2+
]o in 
modulating orthosteric ligands that act on 
mGluR via communication at the hinge 
region of the ECD. We and others have also 
shown that binding of L-Phe and other 
amino acids to a site in the hinge region of 
the CaSR likely communicates with the 
predicted [Ca
2+
]o-binding site at the hinge 
region to increase the sensitivity of the 
receptor to [Ca
2+
]o (12,13,38,39). In recent 
years, increasing numbers of family C 
GPCRs have been found to exhibit 
synergistic modulation of the primary 
orthosteric agonist by allosteric modulators. 
Sweet enhancers binding to the hinge region 
of the human taste receptor are known to 
stabilize the active form of the receptor, thus 
leading to altered perception of sweet taste, 
while IMP and L-Glu also synergistically 
activate the umami taste receptor (40,41). It 
is also interesting to note that an allosteric 
ligand suggested to act at the ECD domain 
of mGluR is located at the hinge region 
(42,43). Thus, our work has strong 
implications for the role of the hinge region 
of the ECD in modulating action of small 
molecule ligands on family C GPCRs.  
As for allosteric modulators targeting the 
TMDs, the binding sites of positive and 
negative modulators of mGluR1α are 
distinct (44). These allosteric modulators 
effectively modulate receptor activation by 
L-Glu, but little is known about the effects 
of the endogenous mineral ion, Ca
2+
, on 
these modulators. In this study, the effects of 
[Ca
2+
]o on CPCCOEt (NAM) and Ro 67-
4853 (PAM) were further assessed.  
 The non-competitive NAM, CPCCOEt, 
is known to inhibit the L-Glu response by 
binding to T815 and A818 on the 7
th
 
transmembrane helix) (45,46). Our data 
shown in Fig. 5 support the contention that 
CPCCOEt, acting as a non-competitive 
inhibitor, also can diminish the [Ca
2+
]i 
response of mGluR1α. Interestingly, 
increasing [Ca
2+
]o restored the [Ca
2+
]o 
sensitivity of the receptor. CPCCOEt not 
only inhibits proliferation of melanoma cells, 
but also reverses morphine tolerance (47,48). 
Thus, the findings in this study indicate that 
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a novel drug targeting the [Ca
2+
]o-binding 
site in mGluR1 has the potential to tune the 
therapeutic effect of CPCCOEt on 
melanoma or addiction. V757 in the TMD 
was revealed to be critical to the activation 
of mGluR1 by the PAMs (27,44). By 
analyzing the [Ca
2+
]i transients and 
oscillations observed here, [Ca
2+
]o not only 
reduced the concentration of Ro 67-4853 
required to initiate [Ca
2+
]i oscillations, but 
also decreased the EC50 value and increased 
the maximal responses of HEK293 cells 
expressing mGluR1 (Fig. 6 and Table 5). In 
the presence of Ro 67-4853, the [Ca
2+
]o 
sensitivity of mGluR1α was also enhanced, 
indicating an allosteric interaction between 
the [Ca
2+
]o-binding site and the site for Ro 
67-4583. Interestingly, Ro 67-4853 only 
enhanced activation of mGluR1α by 
physiological [Ca
2+
]o concentrations, while 
further increases in [Ca
2+
]o abolished the Ro 
67-4853 effect (Fig. 7B) (p < 0.01). This 
indicates that a change in [Ca
2+
]o within the 
physiological range could serve as a PAM, 
similar to Ro 67-4853, and suggests that 
[Ca
2+
]o-induced enhancement of the potency 
of Ro 67-4853 may activate mGluR1 via the 
 
TMDs, and that the activation of the TMDs 
could enhance the sensitivity of the receptor 
to agonist. Since site-directed mutagenesis 
suggests that Ro 67-4853 along with the 
other PAMs, Ro 01-6128, and Ro 67-7476, 
likely share the same binding pocket 
involving V757. [Ca
2+
]o could potentially 
enhance the potencies of other members of 
the Ro and VU series.  
The observed modulation of the effects 
of PAM and NAM by [Ca
2+
]o can be 
explained by the integrated action of the 
ECD domain with the TMDs of the receptor. 
This is supported by our studies using a 
mutation of a key [Ca
2+
]o-binding ligand 
residue, E325I, at the predicted [Ca
2+
]o-
binding site adjacent to the L-Glu-binding 
site. Variant E325I markedly reduces the 
modulation of the action of Ro67-4853 by 
[Ca
2+
]o (Fig. 7). PAMs binding to the TMDs 
have been shown to enhance L-Quis binding 
to mGluR1α (27). It is possible that the 
incomplete reduction in the inhibitory effect 
of MCPG by [Ca
2+
]o is due to an additional 
synergistic effect involving the TMD region 
of the receptor. By tagging the FRET pair 
YFP/CFP to the two intracellular loops 2 
(i2) of the dimeric mGluR1α, Muto et al. 
observed that the re-arrangement of the 
TMD induced by L-Glu was reversed by (s)-
MCPG (49). Such an integrated effect of the 
TMD with the ECD region is further 
supported by studies of mGluRs with 
deletions of the VFT. It was found that 
PAMs not only potentiate the action of 
agonists on the full-length receptors, but 
sometimes can display strong agonist 
activity on VFT truncated receptors (50,51). 
The VFTs of the ECDs are not only 
responsible for agonist-induced activation, 
but also prevent PAMs from activating the 
full-length receptor (50,51). Taken together, 
our study reveals that [Ca
2+
]o-binding at the 
hinge region is likely to be responsible for 
its capacity to modulate action of other 
allosteric modulators. [Ca
2+
]o at 
physiological levels (1.8 mM) enhanced the 
potency of Ro 67-4853 in modulating 
mGluR1α, while increasing [Ca2+]o 
diminished the inhibitory effects of 
CPCCOEt (Figs. 5-7, Tables 4-5). Over the 
past decade, many new PAMs and NAMs 
for various receptors have been developed, 
and the potential exists for developing 
allosteric modulators with greater subtype 
specificity than is possible for orthosteric 
agonists (52). The co-activation induced by 
endogenous agonists and PAMs binding to 
the receptors’ hinge regions could be a 
common feature of family C GPCRs. These 
data provide further insight into the 
modulation of mGluR1α by [Ca2+]o and 
suggest that [Ca
2+
]o has the potential to 
modulate the profile of a variety of agents 
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acting on mGluR1α, including agonists, 
antagonists and allosteric modulators. 
In conclusion, we investigated the 
effects of [Ca
2+
]o on the modulation of 
mGluR1α by orthosteric agonists and an 
orthosteric antagonist, as well as by a PAM 
and NAM, and found that [Ca
2+
]o enhances 
the actions of agonists and PAMs, but 
attenuates the actions of antagonists and 
NAMs. These findings provide new insights 
into the targeting of mGluR1α by different 
classes of ligands. In addition to the specific 
relevance of these findings for 
understanding the nature of allosteric 
modulation of mGluR1α, they may also 
have general relevance for understanding the 
modulation of Family C GPCRs by 
extracellular ions such as Ca
2+
. 
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FIGURE LEGENDS 
 
FIGURE 1. Schematic view of the binding sites for [Ca
2+
]o, L-Glu, L-Quis and (s)-MCPG in 
the mGluR1α ECD. (A) The [Ca2+]o-binding site is highly conserved in group I mGluRs and 
T1R3. In contrast, while sequence alignment suggests that the [Ca
2+
]o binding site is highly 
conserved in group I mGluRs, it is not conserved in other members of the subfamily. (B) L-Glu, 
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L-Quis and (s)-MCPG binding pockets (purple diamond), and scheme of binding sites for 
various classes of ligands acting on mGluR1α. Similar to the L-Glu binding pocket, Y74, R78, 
S165, T188, Y236, D318, and K409 form the L-Quis binding pocket. Similar residues, Y74, 
W110, S165, T188, Y236, D318 and K409, that contribute to the L-Glu binding pocket are also 
involved in binding of (s)-MCPG. L-Glu, L-Quis and (s)-MCPG wedge into a location adjacent 
to the [Ca
2+
]o-binding site in the ECD and maintain the structure of the receptor in its active and 
resting forms, respectively. The residues with more than one dotted lines indicate those that have 
more than one oxygen atom contributing to ligand binding. Most of the positive (orange triangle) 
and negative (cyan pentagon) allosteric modulators have been discovered to bind to TMDs but 
don’t share the same binding site.  
 
FIGURE 2. Correlation maps of WT mGluR1α and D318I, D322I, and E325I. The predicted 
[Ca
2+
]o  binding site is well correlated to the L-Glu-binding pocket. Mutations of the [Ca
2+
]o-
binding site impair the correlation to L-Glu binding pocket. The [Ca
2+
]o-binding site 
corresponding to the x-axis is highlighted by rectangle. 
 
FIGURE 3. Extracellular Ca
2+
 enhances L-Quis activation of mGluR1α by binding to the 
predicted [Ca
2+
]o-binding site. (A-C) Addition of 1.8 mM [Ca
2+
]o (solid dot) increases the L-
Quis-induced [Ca
2+
]i responses mediated by activation of mGluR1α. The response with 0 mM 
[Ca
2+
]o is indicated by the empty circles. In the presence of 1.8 mM [Ca
2+
]o, the L-Quis 
sensitivity of D322I was increased. 1.8 mM [Ca
2+
]o also enhanced the potency of L-Quis on 
E325I. (D) The fold-change in EC50 for activation of WT mGluR1α, D322I and E325I by L-Quis 
upon increasing [Ca
2+
]o  from nominal zero to 1.8 mM. The-fold decreases in the EC50 values for 
WT mGluR1α, D322I and E325I are 4.6, 3.9 and 2.7, respectively. (E) [3H]-L-Quis binds to WT 
mGluR1α in the absence of [Ca2+]o, but mutations in the [Ca
2+
]o-binding site decrease L-Quis-
binding. D318I eliminates L-Quis-binding, while D322I and E325I still retain L-Quis binding. 
An additional 5 mM [Ca
2+
]o enhanced L-Quis binding to WT mGluR1α (p=0.031) and D322I, 
whereas this [Ca
2+
]o effect was abolished in E325I. The binding buffer used was hypotonic 
buffer (N=3). (*p<0.05) 
 
FIGURE 4. Effects of (s)-MCPG on the response of WT mGluR1α to L-Glu and [Ca2+]o. (A) 
Increasing the concentration of (s)-MCPG inhibits mGluR1α in the presence of 5 µM L-Glu, and 
1.5 mM (s)-MCPG entirely blocks the activation of the receptor by L-Glu. (s)-MCPG attenuates 
the responsiveness of mGluR1α to 5 mM [Ca2+]o, and 2.0 mM MCPG does not completely 
inhibit the capacity of the receptor to sense [Ca
2+
]o. (B) 0.5 mM (s)-MCPG competitively inhibits 
L-Glu-induced [Ca
2+
]i responses. Lineweaver-Burk plot analysis indicates that (s)-MCPG 
competes with L-Glu (inset). (C) 0.5 mM (s)-MCPG inhibits low [Ca
2+
]o-induced [Ca
2+
]I 
responses, but high [Ca
2+
]o restores the response of the receptor . (N=3). 
 
FIGURE 5. Effects of CPCCOEt on the responses of mGluR1α to L-Glu and [Ca2+]o. (A) In 
the presence of 10 or 40 µM C CCOEt, the sensitivity of mGluR1α to L-Glu was reduced. The 
maximal response was reduced to about 50% in the presence of 40 µM CPCCOEt. (B) The 
[Ca
2+
]o sensitivity of wild type mGluR1a was reduced by the addition of 5 or 40 µM CPCCOEt. 
[Ca
2+
]i was measured using Fura-2 AM in the absence (solid dots) or presence of 5 µM (solid 
square) or 40 µM (empty circle) CPCCOEt. In the cells inhibited by CPCCOEt (5 or 40 µM), 
increasing [Ca
2+
]o counteracts the inhibitory effects of CPCCOEt. HEK293 cells transiently 
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expressing WT mGluR1α were mounted on coverslips, and the [Ca2+]i change indicated by fura-
2AM was collected. (N=3).  
 
FIGURE 6. [Ca
2+
]o and Ro 67-4853 co-activate mGluR1α. HEK293 cells growing on 
coverslips were transiently transfected with wild type mGluR1α. After dye loading, the cells 
were pre-incubated in 10 mM HEPES, 140 mM NaCl, 5 mM KCl, 0.55 mM MgCl2, 0.5 mM 
CaCl2 and 5 nM Ro 67-4853 (pH 7.4) for 10 min. (A) 10 or 100 nM Ro 67-4853 enhances the L-
Glu sensitivity of mGluR1α. (B) 30 or 300 nM Ro 67-4853 increases the [Ca2+]o sensitivity of 
mGluR1α (C) Addition of [Ca2+]o and Ro 67-4853 to the cells. Ro 67-4853 displayed activity on 
mGluR1α in the presence of 0.5 mM [Ca2+]o, while 1.8 mM [Ca
2+
]o enhanced its potency. (* p < 
0.05; ** P < 0.01; # P = 0.05) 
 
FIGURE 7. E325I retains the enhanced responsiveness of the receptor to 10 µM Ro 67-4853 
in the presence of L-Glu but loses its potentiation by [Ca
2+
]o. (A) Addition of 30 µM L-Glu 
increases the Ro 67-4853 sensitivity of E325I in the presence of 1.8 mM [Ca
2+
]o (P=0.014). (B) 
E325I responds to 10 µM Ro 67-4853 in the absence of both [Ca
2+
]o and L-Glu. Increasing 
[Ca
2+
]o from 0 to 5.0 mM had no effect on the response of E325I to Ro 67-4853, while the 
activity of WT mGluR1 to Ro 67-4853 was progressively enhanced to increases in the [Ca
2+
]i 
response of E325I (N=3) (*p < 0.05). Both WT mGluR1 and E325I have stronger responses 
while exposing to 10 and 20 µM Ro 67-4853 in the presence of 5 mM Ca
2+
, respectively. 
(*P<0.05) 
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Table 1. Mutations in the [Ca
2+
]o-binding site perturb the correlated motions between the 
[Ca
2+
]o-binding site and the L-Glu-binding site of mGluR1α 
 
 D318 D322 E325 
WT W110, S165, T188, 
D208, Y236, D318, R323 
W110, S165, T188, 
Y236, D318, R323 
R323 
D318I D208, G293, D318, 
R323 
G293, D318, R323 G293, D318, R323 
D322I Y74, W110, G293, D318, 
R323, K409 
D318, R323 Y74, G293, D318, R323 
E325I Y236, G293, D318, R323 G293, D318, R323 G293, D318, R323 
 
 
*Based on the correlation map shown in Figure 2, there is correlated motion between the 
reported L-Glu-binding pocket and the [Ca
2+
]o-binding site (D318, D322 and E325). The 
residues with absolute correlation values greater than 0.3 are listed in this table. Of note, WT has 
five residues (shadowed residues are not included because they reside in the same loop as the 
[Ca
2+
]o-binding site and thus would have same motion) in the L-Glu-binding site that correlate 
with [Ca
2+
]o-binding 1, while there are only correlations between two residues in variants D318I 
and E325I, and four in D322I. Shadowed residues are in the same loop as the [Ca
2+
]o-binding site, 
and they have same movements as the [Ca
2+
]o-binding site by default. 
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Table 2. Effects of [Ca
2+
]o on the responses of WT-mGluR1α and variants with mutations  
[Ca
2+
]o-binding site 1 to L-Quis.  
[Ca
2+
]i response increase induced by increasing L-Quis via WT-mGluR1a, D322I and E325I 
were measured in both Ca
2+
-free saline and buffer with physiological Ca
2+
. 
 
[Ca
2+
]o 
concentration 
(mM) 
WT D322I E325I 
EC50 
(nM) 
Maximal 
Response 
(%)
a
 
Fold decrease 
in EC50 
EC50 
(nM) 
Maximal 
Response 
(%)
a
 
Fold decrease 
in EC50 
EC50 
(nM) 
Maximal 
Response 
(%)
a
 
Fold decrease 
in EC50 
0 12.8 37 ± 4 4.6 12.4 80 ± 16 3.9 20.6 60 ± 8 2.7 
1.8 2.8 37 ± 5 3.2 96 ± 21 7.6 88 ± 8 
KD (mM)
b 
0.3 0.6 >20.0 
a. The maximal responses are normalized to the maximal response of WT mGluR1α to L-
Glu 
b.  [Ca2+]o-binding affinity of mGluR1α in the presence of 30 nM [
3
H]-L-Quis (E325I with 
300 nM [
3
H]-L-Quis)  
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Table 3. Addition of 0.5 mM (s)-MCPG decreases the responses of mGluR1α to [Ca2+]o and 
L-Glu.  
The [Ca
2+
]i response to [Ca
2+
]o and L-Glu in the absence or presence of 0.5 mM (s)-MCPG were 
obtained by measuring the ratiometric change of Fura-2 AM fluorescence. 
 
(s)-MCPG 
(mM) 
 
Response to [Ca
2+
]o Response to L-Glu 
EC50 (mM) nHill Maximal Response
a
 EC50 (µM) Maximal Response
a
 
0 3.5 6.4 85 ± 2 1.7 100 ± 2 
0.5 6.0 2.6 67 ± 2 3.7 97 ± 5 
 
a. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu 
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Table 4. The effects of CPCCOEt on the responsiveness of mGluR1α to L-Glu and [Ca2+]o 
(N=3).  
WT mGluR1α was incubated with increasing concentrations of [Ca2+]o with either 0, 5 or 40 nM 
CPCCOEt (left side) or to increasing concentrations of L-Glu in the presence of the indicated 
fixed concentrations of CPCCOEt. 
CPCCOEt 
Conc. (nM) 
Response to [Ca
2+
]o Response to L-Glu 
EC50 (mM) nHill Maximal Response 
(%)
a
 
EC50 
(µM) 
Maximal Response 
(%)
a
 
0 3.5 6.4 85 ± 2 1.7 100 ± 2 
5 7.6 1.3 75 ± 3 - - 
10 - - - 5.2 44 ± 8 
40 14.7 1.1 60 ± 3 10.1 30 ± 10 
a. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu 
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Table 5. [Ca
2+
]o effects on modulation of mGluR1α by Ro 67-4853 (N=3). 
WT mGluR1α  was incubated with increasing concentrations of Ro 67-4583 with either 0.5 or 
1.8 mM [Ca
2+
]o (left side) or to increasing concentrations of [Ca
2+
]o in the presence of the 
indicated fixed concentrations of Ro 67-4583.  
 
[Ca
2+
]o Conc.  EC50
a
  Max. Res.
c
 Ro 67-4853 Conc.  EC50
b
  Max. Res.
c
 
0.5 (mM) 20.7 (nM) 50 ± 8 0 (nM) 3.5 (mM) 85 ± 2 
1.8 (mM) 10.0 (nM) 59 ± 4 30 (nM) 2.1 (mM) 83 ± 6 
   300 (nM) 0.7 (mM) 83 ± 2 
a. Refers to EC50 of Ro 67-4853 
b. Refers to EC50 of Ca
2+
 
c. The maximal responses are normalized to the maximal response of WT mGluR1α to L-Glu.  
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Table 6. Analysis of ligand interaction by LPC server 
PDB files bound with L-Quis, L-Glu and (s)-MCPG were analyzed by the online LPC server. 
The output, including distance, surface interacting and atom number contributing to binding, 
were as summarized below. 
Residue 
Number 
Distance (Å) Surface (Å
2
) Number of contacts 
L-Quis L-Glu (s)-MCPG L-Quis L-Glu (s)-MCPG L-Quis L-Glu (s)-MCPG 
Y74 2.7 2.5 2.6 29.4 37.3 46.7 9 7 7 
R78 - 5.1 5.5 - 0.3 1.6 - 1 1 
W110 3.6 3.9 3.9 37.1 20.2 28.5 8 8 9 
G163 3.7 3.9 4.8 8.5 8.7 2.7 2 2 1 
S164 3.1 3.5 4.8 23.6 7.3 8.3 3 3 4 
S165 3.0 2.7 2.9 35.7 43.7 46.6 4 4 7 
S166 - - 4.4 - - 0.7 - - 1 
S186 3.5 2.8 3.7 26.5 29.3 27.2 5 5 10 
A187 3.6 3.3 - 1.6 1.6 - 1 1 - 
T188 3.8 2.9 3.2 3.9 27.9 27.0 2 4 3 
S189 - - 5.0 - - 2.7 - - 3 
D208 - - 4.8 - - 0.9 - - 2 
Y236 3.6 3.4 4.2 42.9 40.4 46.7 10 14 13 
E292 3.9 5.0 - 22.2 5.0 - 7 5 - 
G293 3.7 5.1 - 25.9 1.2 - 3 1 - 
M294 4.6 - - 3.3 - - 2 - - 
D318 3.7 2.8 5.0 19.8 31.3 9.5 3 2 4 
G319 3.4 3.7 6.2 19.2 21.4 1.3 4 3 2 
R323 3.5 3.7 6.1 15.5 10.4 3.1 3 1 1 
K409 2.8 3.6 3.1 32.2 23.9 30.0 3 4 4 
 
 
“-“ means no contacts 
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                       318  322 325 
mGluR1       LIGSDGWADRDEVIE 328 
mGluR5       LLGSDGWADRYDVTD 315 
T1R3         WVASEAWLTS-DLVM 311 
mGluR2       WVASDGWG-ALESVV 305 
mGluR3       WVASDGWGAQ-ESII 311 
mGluR7       WVGSDSWGSKINPLH 324 
mGluR6       WVGSDSWGAKTSPIL 317 
mGluR4       WMGSDSWGSKIAPVL 322 
mGluR8       WIGSDSWGSKIAPVY 319 
T1R2         WIASESWAIDPVLHN 312 
T1R1         WVASEAWALSRHITG 311 
CaSR         WLASEAWASSSLIAM 307 
GABAbR1      VKLFEKWGWKKIATI 312 
GABAbR2      QWIIPGWYEPSWWEQ 292 
GABAbR3      LAPTSACPSAILLKA 331 
 
A 
B 
Figure 1 
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WT D318I
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